0001654954-23-003383.txt : 20230323 0001654954-23-003383.hdr.sgml : 20230323 20230323070355 ACCESSION NUMBER: 0001654954-23-003383 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20230323 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 23754429 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr_8k.htm FORM 8-K mnpr_8k.htm

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 23, 2023

 

MONOPAR THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-39070

 

32-0463781

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

1000 Skokie Blvd., Suite 350, Wilmette, IL

 

60091

(Address of principal executive offices)

 

(Zip Code)

 

(847) 388-0349

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value

 

MNPR

 

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

Item 2.02 Results of Operations and Financial Condition

 

 On March 23, 2023, Monopar Therapeutics Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022. A copy of this press release is attached hereto as Exhibit 99.1.

 

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing

 

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1 

 

Press Release Dated March 23, 2023

 

 
2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Monopar Therapeutics Inc.

    
Date: March 23, 2023By:/s/ Kim R. Tsuchimoto

 

Name:

Kim R. Tsuchimoto 
 Title:Chief Financial Officer, Secretary and Treasurer 

 

 
3

 

 EX-99.1 2 mnpr_ex991.htm PRESS RELEASE mnpr_ex991.htm

EXHIBIT 99.1

 

Monopar Therapeutics Reports

Fourth Quarter and Full-Year 2022

Financial Results and Recent Developments

 

Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next Week

Camsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m2)

 

Wilmette, IL, March 23, 2023 – Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2022 financial results and summarized recent developments.

 

Recent Developments

 

Validive – International Phase 2b/3 Trial, Interim Go/No-go Analysis on Track for End of Next Week

 

 

·

The VOICE trial, in planning for a potential positive go/no-go outcome from the interim analysis, continues to enroll patients in the Phase 3 portion of the VOICE trial and add additional clinical sites (now at 81 active sites across the U.S. and Europe).

 

 

 

 

·

The blinded interim analysis of clinical data from the Phase 2b patient cohort of the trial, to be performed by an independent data monitoring committee, will be used to recommend the Company either continue enrolling the Phase 3 portion of the trial or to stop the trial. This analysis should be completed and reported out by the end of next week.

 

Camsirubicin – Phase 1b Dose-Escalation Trial, Now Enrolling Fifth Dose-Level Cohort

 

 

·

Monopar is currently enrolling patients into the fifth dose-level cohort (650 mg/m2), which is nearly 2.5x the highest dose evaluated in any prior camsirubicin clinical trial (265mg/m2).

 

 

 

 

·

Phase 1b data to date show an improvement in median progression free survival from what was observed in the prior camsirubicin Phase 2 trial (265 mg/m2). This is supportive of our dose-response hypothesis with camsirubicin.

 

 

 

 

·

To date, no drug-related cardiotoxicity has been observed with camsirubicin treatment as evaluated by the industry standard left-ventricular ejection fraction (LVEF). This compares favorably to the well-documented dose-restricting cardiotoxicity experienced with doxorubicin, the current first-line treatment for advanced soft tissue sarcoma (ASTS).

 

 

 

 

·

75% of camsirubicin patients in this trial have experienced no hair loss. Of the 25% with any hair loss, only 8% experienced >50% hair loss and only 17% experienced low grade hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss.

 

 

 

 

·

Only 8% of camsirubicin patients in the trial have experienced low grade, mild oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis.

 

 

 

 

MNPR-101 for Radiopharmaceutical Use – Promising Preclinical Studies Support FIH Study

 

 

·

 MNPR-101-Zr is a zirconium-89 labeled version of MNPR-101, a highly selective antibody against the urokinase plasminogen activator receptor (uPAR). Positron emission tomography (PET) imaging of preclinical mouse models for triple-negative breast, colorectal, and pancreatic tumors displayed high and selective uptake of MNPR-101-Zr in these uPAR-expressing tumors.

 

 

 

 

·

 Based on the promising recently generated preclinical imaging results with MNPR-101-Zr, Monopar and its collaborator, NorthStar Medical Radioisotopes, LLC committed to additional funding with the aim of initiating a first-in-human (FIH) imaging study with MNPR-101-Zr as early as the end of this year.

 

 

 

 

·

 These proof-of-concept studies provide support for a FIH PET imaging study with MNPR-101-Zr and a future therapeutic study using the previously announced actinium-225 labeled radioimmunotherapeutic version of MNPR-101. Overall, the imaging results demonstrate the potential utility of MNPR-101 as a precision targeting agent for both imaging and therapy in multiple cancer indications.

 

MNPR-202 - Promising Preclinical Data Ignites Further Research

 

 

·

MNPR-202 is designed to retain the same potentially non-cardiotoxic backbone as camsirubicin but is modified at other positions which may enable it to work in certain cancers that are resistant to camsirubicin and doxorubicin.

 

 

 

 

·

Monopar’s collaborator at the National University of Singapore, Cancer Science Institute, has reported data from blood cancer preclinical studies showing that MNPR-202:

 

 

-

has a similar cytotoxic potency to doxorubicin

 

-

generates increased DNA damage in the cancer cells compared to doxorubicin

 

-

has a unique immune activation profile versus doxorubicin

 

-

demonstrates increased apoptosis (programmed cell death) compared to doxorubicin

 

-

causes a distinct set of genes to be upregulated and downregulated versus doxorubicin and

 

-

may also be superior to doxorubicin in certain combination treatment regimens.

 

 

·

A combination drug screen with 183 compounds was performed, revealing distinct differences in the synergy profile between doxorubicin and MNPR-202 when used along with other compounds. For example, MNPR-202 demonstrated a more favorable synergy profile with the experimental anti-cancer agent volasertib compared to doxorubicin.

 

Kim R. Tsuchimoto Appointed as New Board Member

 

 

·

On March 20, 2023, the Company increased its Board size from five to six members.

 

 

 

 

·

Simultaneously, Monopar appointed Kim R. Tsuchimoto, the Company’s Chief Financial Officer, to the Board to serve until the next annual stockholders’ meeting.

 

 
2

 

 

 

·

Ms. Tsuchimoto brings over 25 years of experience in the biopharma industry, which includes previously serving as Vice President at BioMarin Pharmaceutical and Chief Financial Officer at Raptor Pharmaceutical. She was involved in BioMarin’s initial public offering onto Nasdaq in 1999, Raptor’s reverse merger onto Nasdaq in 2009, and Monopar’s initial public offering onto Nasdaq in 2019. She brings strong financial management, corporate governance and financial strategy experience to Monopar’s Board.

 

Results for the Fourth Quarter and Year Ended December 31, 2022, Compared to the Fourth Quarter and Year Ended December 31, 2021

 

Cash and Net Loss

 

Cash, cash equivalents and short-term investments as of December 31, 2022, were $13.1 million. Monopar expects that its current funds will be sufficient for Monopar to obtain topline results from its ongoing open-label Phase 1b camsirubicin clinical trial as planned by the end of 2023 (but this may not be the case if camsirubicin reaches even higher dose levels than anticipated and topline results are deferred as dosing continues beyond 2023) and the continued enrollment in the Phase 3 portion of the ongoing Validive Phase 2b/3 (VOICE) clinical program should the interim analysis yield a “go” decision. Monopar will require additional funding and/or a corporate partner to advance its clinical and preclinical programs and anticipates that it will seek to raise additional capital and/or engage a partner within the next 12 months to fund its future operations. 

 

Net loss for the fourth quarter of 2022 was $2.9 million or $0.22 per share compared to net loss of $2.7 million or $0.21 per share for the fourth quarter of 2021.  Net loss for the year ended December 31, 2022 was $10.5 million or $0.83 per share compared to net loss of $9.1 million or $0.73 per share for the year ended December 31, 2021.

 

Research and Development (R&D) Expenses

 

R&D expenses for the fourth quarter of 2022 were $2.1 million compared to $2.0 million for the fourth quarter of 2021. This increase of $0.1 million was primarily due to 1) an increase of $0.3 million for VOICE clinical trial expenses, and 2) an increase in $0.1 million in R&D consulting partially offset by a decrease of $0.3 million in R&D personnel expenses.

 

R&D expenses for the year ended December 31, 2022 were $7.6 million compared to $6.5 million for the year ended December 31, 2021. This increase of $1.1 million was primarily due to 1) an increase of $1.0 million for VOICE clinical trial expenses, 2) an increase of $0.5 million for camsirubicin Phase 1b clinical trial expenses, and 3) increase of $0.2 million in R&D consulting partially offset by 1) a decrease of $0.5 million in R&D personnel expenses and 2) a decrease of $0.1 million in preclinical program expenses.

 

 

General and Administrative (G&A) Expenses

 

G&A expenses for the fourth quarter of 2022 were $0.8 million, compared to $0.7 million for the fourth quarter of 2021. This increase of $0.1 million was primarily due to an increase in G&A personnel expenses.

 

G&A expenses for the year ended December 31, 2022 were $2.9 million, compared to $2.6 million for the year ended December 31, 2021. This increase of $0.3 million was primarily due to an increase in G&A personnel expenses.

 

 
3

 

 

About Monopar Therapeutics

 

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® (Phase 2b/3) for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, and links to SEC filings that contain detailed financial information, visit: https://ir.monopartx.com/annual-reports

 

Forward-Looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward- looking statements include statements concerning: Monopar’s plans to continue to activate Validive clinical sites in both the U.S. and Europe; that the VOICE trial interim analysis should be completed and reported out by the end of next week; that Monopar and its collaborator, NorthStar Medical Radioisotopes, LLC are aiming to initiate a first-in-human imaging study with MNPR-101-Zr as early as the end of this year; and that Monopar expects that its current funds will be sufficient for Monopar to obtain topline results from its ongoing open- label Phase 1b camsirubicin clinical trial as planned by the end of 2023 (but this may not be the case if camsirubicin reaches even higher dose levels than anticipated and topline results are deferred as dosing continues beyond 2023) and the continued enrollment in the Phase 3 portion of the ongoing Validive Phase 2b/3 (VOICE) clinical program. The forward-looking statements involve risks and uncertainties including, but not limited to: not completing and reporting out the VOICE trial interim analysis by the end of next week; reaching a no-go decision based on the interim analysis; uncertainty of the continuation of the Validive program if the interim analysis is negative; if the interim analysis is positive, not successfully recruiting patients and initiating additional clinical trial sites for the Phase 3 portion of the VOICE trial or the camsirubicin Phase 1b clinical trial within expected timeframes, if at all; the camsirubicin trial data being inconclusive or negative; the Company’s inability to raise sufficient funds or engage a partner to complete the Phase 3 portion of the VOICE clinical trial and continue the camsirubicin clinical program through and beyond the Phase 1b clinical trial; potential ramifications due to recent instability in the banking industry; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

 

Contact

Kim R. Tsuchimoto

Chief Financial Officer

kimtsu@monopartx.com 

 

Follow Monopar on social media for updates: 

 @MonoparTxMonopar Therapeutics

 

 
4

 

 EX-101.SCH 3 mnpr-20230323.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mnpr-20230323_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Ex Transition Period Entity Incorporation State Country Code Entity Tax Identification Number Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Entity File Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name EX-101.CAL 5 mnpr-20230323_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 mnpr-20230323_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 mnpr-20230323_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 8 mnpr_ex991img3.jpg begin 644 mnpr_ex991img3.jpg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end GRAPHIC 9 mnpr_ex991img2.jpg begin 644 mnpr_ex991img2.jpg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end GRAPHIC 10 mnpr_ex991img1.jpg begin 644 mnpr_ex991img1.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 23, 2023
Cover [Abstract]  
Entity Registrant Name MONOPAR THERAPEUTICS INC.
Entity Central Index Key 0001645469
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Mar. 23, 2023
Entity Ex Transition Period true
Entity Incorporation State Country Code DE
Entity Tax Identification Number 32-0463781
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity File Number 001-39070
Entity Address Address Line 1 1000 Skokie Blvd.
Entity Address Address Line 2 Suite 350
Entity Address City Or Town Wilmette
Entity Address State Or Province IL
Entity Address Postal Zip Code 60091
City Area Code 847
Local Phone Number 388-0349
Security 12b Title Common Stock, $0.001 par value
Trading Symbol MNPR
Security Exchange Name NASDAQ
XML 12 mnpr_8k_htm.xml IDEA: XBRL DOCUMENT 0001645469 2023-03-23 2023-03-23 iso4217:USD shares iso4217:USD shares 0001645469 false 8-K 2023-03-23 MONOPAR THERAPEUTICS INC. DE 001-39070 32-0463781 1000 Skokie Blvd. Suite 350 Wilmette IL 60091 847 388-0349 Common Stock, $0.001 par value MNPR NASDAQ false false false false true true EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( 'HX=U8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !Z.'=64IN<<>X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VU$)'1[43PI""XHWD(RNQML_I",M/OVIG6WB^@#>,S,+]]\ M ]/I*'5(^)Q"Q$06\]7D!I^ECAMV((H2(.L#.I7KDO"EN0O)*2K/M(>H](?: M([2?)K^+N?OO ^I:WHN*B:L6V:207\OKV?7;]X7<1=L'8G?W' MQF?!OH-?=]%_ 5!+ P04 " !Z.'=6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M 'HX=U8WT][&;P0 )H1 8 >&PO=V]R:W-H965T&UL MC9A=<^(V%(;_BL;M]&H3_$& I, ,(:3+;$)<8)N9=GHA; &:V)(KRT#^?8]L ML-G6''.#+=OGY;$^WG/D_EZJCW3+F":'.!+IP-IJG3RT6FFP93%-;V7"!-Q9 M2Q53#4VU::6)8C3,@^*HY=IVIQ53+JQA/[_FJV%?9CKB@OF*I%D<4_7YR"*Y M'UB.=;HPYYNM-A=:PWY"-VS!]/?$5]!JE2HACYE(N11$L?7 &CD/CV['!.1/ M_,'9/CT[)^955E)^F,8T'%BV(6(1"[21H'#8L3&+(J,$'/\<1:WR/TW@^?E) M_3E_>7B9%4W96$;O/-3;@=6S2,C6-(OT7.Z_LN,+W1F]0$9I_DOVQ;-MVR)! MEFH9'X.!(.:B.-+#L2/. CSG0H![#'!S[N*/*/,TJ)F3_%7S M:(#CPHS*0BNXRR%.#\=RQU2_I4'*7&@%Q[#'(LR]$/9*U2UQO2_$M5WOQ_ 6 M$)08;HGAYGH>AD'^&JU2K6"@_JXC*A3:]0IF]CZD"0W8P(+IF3*U8];PEY^< MCOTKPN>5?!ZF/IP(S?4GF;,--X1"DQF-61TEKO/Z-GOS1W.R_#J9C_S)]^5T MO"#3V?@686R7C.UK&,=, &%$IB)D!_*-?=91XDJV;3N=]EV[B6'-UK MQF@2,[7A8D-^@WB])6,9)U34CA2NIU6&8?5*K-YU8^0SQ65()B(D8">UPX4K ME<;0Y SW)=K]53UV($M8=RG/O;S K*/#Q1JZR[$KU[2OH9J*0*I$*II3+31T M&8QE!@L0UJ$,:_NO0?EI@@&>V;IS#>"2'L@TA)'E:QX4E+,L7EVP?%S20=WYX6,> S#!;F M*PREXC2JY<%5&GDJ0W=P'_85R[N'B8 5%@HN!GGR;;V^,(*X7B-9Y>D.[LK_ M(YNF:09DC8"X;"-@Y?<.;MC'^?_,(X;->%P$TN"-=V]W;0RILG[G*N\?A2'4 M)VEY?(''B%-+A^LYD*;)XD-^<$8>HUV(U1!.E0D6$M=;9!Q,T;M# M^[!*!LY5V>!$-3:--YAV7,Q1#8(=V[['DH![5O;CWIT/ MX BVDY=1<(%>NXN!5-;OXJ;](@/H$W\K!>87#2)>KW=C>VVL:G8K\W=QLUZP M(%.F>QQW199<1_7=@XL8C\XK$QE\?"$_V[=@:22ABNQHA)9";I4*7-RSH2P+ M3<99_X<(ZD\W\7MNNRQR2'84K%A%S=I#4*ST>)I]'L=4^ML MIVV^6D"Y"W5\2B*V!B7[M@NOJHH/ 45#RR3??*^DAJU\?KIE%'*D>0#NKZ74 MIX;9SY>?8X;_ E!+ P04 " !Z.'=6GZ ;\+$" #B# #0 'AL+W-T M>6QEO%DN7/Z MZZ>S;"=I=67=A['-HN M6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2 MK"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP( M&K XU7=>&18/QA<0&>7= MJ?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N- M9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W] MK;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LU MF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ> MDO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A M'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/ M9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@> MF*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%' M, ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " !Z.'=6EXJ[', 3 M @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/ MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%" MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( 'HX=U:J MQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A M#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B M;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X" M$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S; M%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z M0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&) M)@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y> M9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " !Z.'=6)!Z;HJT #X M 0 &@ 'AL+U]R96QS+W=O[IFBG#S^0W1U MW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@ M;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ >CAW5F60>9(9 M 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL M6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4 M'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY M'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?K MT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y; M@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$" M% ,4 " !Z.'=6!T%-8H$ "Q $ @ $ 9&]C M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( 'HX=U92FYQQ[@ "L" 1 M " :\ !D;V-0&UL4$L! A0#% @ >CAW5C?3WL9O! FA$ !@ M ("!#0@ 'AL+W=O7!E&UL4$L%!@ ) D /@( ' 84 $! end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://monopartx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports mnpr_8k.htm mnpr-20230323.xsd mnpr-20230323_cal.xml mnpr-20230323_def.xml mnpr-20230323_lab.xml mnpr-20230323_pre.xml mnpr_ex991.htm http://xbrl.sec.gov/dei/2022 true true JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mnpr_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "calculationLink": { "local": [ "mnpr-20230323_cal.xml" ] }, "definitionLink": { "local": [ "mnpr-20230323_def.xml" ] }, "inline": { "local": [ "mnpr_8k.htm" ] }, "labelLink": { "local": [ "mnpr-20230323_lab.xml" ] }, "presentationLink": { "local": [ "mnpr-20230323_pre.xml" ] }, "schema": { "local": [ "mnpr-20230323.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mnpr", "nsuri": "http://monopartx.com/20230323", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mnpr_8k.htm", "contextRef": "From2023-03-23to2023-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://monopartx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mnpr_8k.htm", "contextRef": "From2023-03-23to2023-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://monopartx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001654954-23-003383-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-003383-xbrl.zip M4$L#!!0 ( 'HX=U83BB1*C@0 )(6 1 ;6YP!T0]X&FJ9M8A*ID90O M_[Z'U,62+3F2G(?Z2=3YOG/7(>GIYUT4H@V5B@E^[03>P$&4$[%@?'7M),K% MBC#F(*4Q7^!0<'KM[*ER/M_\^LOT-]=]O9L]H0=!DHARC>XEQ9HNT);I-3*B M;UAI*ETW0_^3VIF@H3?R!I^*]W=8 4MPRP%A4$@>0!\22T2,9DL=C/SAT!\. MAJ,"]"*6>HLE15B2-=.4Z$3B$"VH8BN.P'&4!C1!M[\3]+#&,L*QI!'F)BAT MN]%>H>M>Q'O)5FN-_B!_(F,&/;K/7[ZCNT0Q3I5"+R),C"OJ WKDQ$.W88AF MAJ'0C"HJ-W21J5-D#4809)BKR2Z\=M9:QQ/?WVZWWFXN0T_(%40"$;T^,?Z? MDR$E739"KWR0YD"22 G%VA=HBU24>"NQ\7.IR=4PIT!%5QC'+M:Z8"VQFEO] MF= 'H63S1$.=,YIBI-X(""KZZ8ZLZY%&4H$ROJ%*UX-3&<"#D3L(W%&0DSA= MF0YKS,_8ER*D?@8K6)@156_)BHY3I/GM*'H*L-I81S^'K*C2#E)W!,VZ^=%+!+XZ* ME($_^JFP F6UT*L4RHK&%0G7LJEO4V&U)EJ>*3E(BVI(W52]0E31O-#RB%#1 M#V+?B UG8%IQ&)1-F69K,&5%55.4U4<,@@J0)]$;W@""2D8*@N M.(*[1SSP ML];YNI'1/"[*X(B7OH9($9$=V8/1<.2@8KY\%3)ZH$N="VTW$+&$=QXPOA5V@ MJ?E0)J9FWR%7R#S\/7MLT&M'S+V 7=-!#&91^I@JRC0MZ))Q9HT-S"] [F&; M=)%E3/UC:%E# EOB7_S&/L-FI8!HG3<[1<;,($TL@D.2A!U)!V\:.-FK/%7E M].7#9D:7R ZIB6F\:T>Q* [-2+'OUG9_,XWBY@7Z%P+TH(%RB%%^9DC9_!_G M)#.JEK,$?M]].% M!)W>-:3JQ_'>$4W]TDB"165>32$>(37B)S/OW":>GD"?!+%ZSE#,RLUYKGGE M!D,X=WD[M6MG.X>:AO<46)YHVQ2XSGU.B*?K8=%IP=8DG_;SH MYT+3M:I5_@N\?>I9 7OJSN8=G >)=NDN#N$ZK87_F0X=TY(R+>J)\IVW5% ="^MAS%!S^#&AE-8>;A_86&R]99VV> MW&Y\&FIUT-'3?OD^V=>^U7'I*"Q?3YL<>8MIUZI'V0__<[2K>XZW3STR#Q?/ M[H4OWU;3Y.=J^GG0O?2U'G2L?LTMO6_?]8JZ=.&_(&C[%V35_M1/]=W\ %!+ M P04 " !Z.'=6@]/7<-T! "5 P %0 &UN<'(M,C R,S S,C-?8V%L M+GAM;(U3.V_;,!#>"_0_7-6A+5"*>BRQ8"?P(X,!)X/=%ED9ZFP1I4B!I"SY MWY>4(S=&&R :!%'WO>YTFM[UM80C&BNTFD5IG$2 BNM2J,,L:BUAE@L1@75, ME4QJA;/HA#:ZN_WX8?J)D*?%=@,KS=L:E8.E0>:PA$ZX"D+I@5F'AI 7]*^S M3P%9G,?)S>7]@EG/TFK@^&)ZJ:R\'N@]\* \4).<9AG-DBR_@'9Z[SIF$)CA ME7#(76N8A!*M."CPP>'<4 'S+QQ6%3,U:PS63(6F8'YT\45KJ9N3$8?*P5?^ M#8(-K,GC_0]8M%8HM!9V6K8ABOT.:\5CF$L)V\"PL$6+YHCEBYP4ZG<1;L^^ M/_"#5K;HK9A%E7--06G7=7&7Q]H-CM>^5Q$J#!PCM'("BK_XZ63 MR80.U1'Z#[)_-G+TR.D8Q\.M*.Q@M]%\&.X[:/ F(IS(""/A%4DSDJ=Q;\O( M3P/@/ ^C)6YQ#Q >?F[7%]-:*]TPX_J8ZYJ&*EUJOYD^Z4"L#.YG4:T:0\)G M2?(L#]J?KT#NU/@-M:)NI&^1OO+E3/)6#GUN_/D*C[U#56(YJ@3S=^=RP@5T M/80OOE<>>_-;LM=_ D.0<<4JO-N7V#U!+ P04 " !Z.'=6 MA*2+,9<" !." %0 &UN<'(M,C R,S S,C-?9&5F+GAM;+U56VO;,!1^ M'^P_G'D/VV"R')O"&IJ6M-U#(1TCW4;?BB*?Q&*R9"0YEW\_R8Z]A*;0#+(\ M!-OGNYUC6;JX6I<2EFBLT&H4#>(D E168>&D"WZ5^LSA#3.XN1+ M__R:6<_2JN'XXJ"OW'H]T'/@0;FA)AE-4YHF:=:#'O3ZT;76V,6!0./O)/$&S@CGS[ M^@.N:RL46@L/6M8ABOT,=XK',)82IH%A88H6S1+SK9P4ZOQP M;<4H*IRKAI2N5JMXE<7:+'P_R8 ^WD\>>.%S$:'"P#E&'2NH'.(-SL_/:5/M MH,^0ZYF1G4=&NSB]LJ_FKB?L@L]H6_10*X:V23;1O'D/KW" %Q'ACG0P$AZ1 M04JR0;RV>>0'!]".SFB)4YP#A(N?T[O>M-1*5\RX=89&D6M-_O@=RF\HO9BK*2?AITQ]N]&%YLX: MZ\)+&%[/D.3"?ROA,XA@:[3;6J\BE*,>2K<8>E#@U*E[*Y+KDHDC(S]GGSQO MXT-*+&?A11\5=I]ZZJ1,RN/R-813IU+:C8\-UG'^XUK$.:NE^^?%V-%W$_N' M0HFPM4W\[5YJ7#M4.>9=[B#WZJW("1?02?L; /E[6A)HD/"=+= ?)7/MCZ40 MH-T"NV!2\[TT,NS VCP?HNVZM\CCA5[2'$4X)]-P$?;!M!TCBJ?&=SRSSC#N M.B7)9B@;_2>/V3:Q'1$],*-PPM&](^[R#U!+ P04 " !Z.'=6>CXX74H& M #(.P %0 &UN<'(M,C R,S S,C-?;&%B+GAM;,U;76_;-A1]'[#_<.<] M; ,F*U: 83&:%JZ;%L;<)(C=K=@P%+)$V\0DTB#IV/[W(_5A6Q(I)4%+Z261 MQ7/(O5F'T?PB!C'E%SW!OV+'B 2T!"3U75ORQV?!QCW@ N?A'Y$ M";KN'1#OO7G]_7>O?G"M?]B]^/YY_ZW/)HB3AR,;!L>6=[ _H$@+5+?V6>QO&(I]HH*"T:/H'_L: MT\V!X=5:P,_!+Z"&@8ES>S.'MUN.">(<9C3:*BG\5YB0H ^C*(('Q>#P@#AB MCRC,NHLP^6^H_BQD?" GFO#AGN/KWEJ(S=!U=[M=?W?9IVPEX[D8N)\_3F?! M6NIR,%$3'J!>SE*]Z'B#JZLK-VG-H17D?L&B?(Q+-Y3+=<@:>2L28J_@N02ME-#7,E1IF\)L:YL?L]-1?H*@'"OGI86*,ZJK05T9RGRCU M>9W?(X9I>$/R4;Y2H.5NGRK^JPX_$SX3+YKR*M]R ',J_.A%TL^9ED7?HI?- M]HEG>Y9EU4DQXY"OHK^NB&"*O;IJ<.''60A"P_?!E3N0 8 M+;A@?B#RGI(@KGN:=K$I>,QMI!LYBI MIO%+M#CRTTF10VAE%D ,<;IE 7I6/LZUFF8HTQ-'$J%648@XGV:]UPD&_LE1 M_[YR3[U\\Q3?$('%X0&ML!J=B%L_1IHX]# [":^3F.==A^E ^FMDE5V00N&$ M!05NP0MCN6"7J^2)+$G[/]#!&%4%9],-!I%%.Y1 G?I?!$!D8$C1(N%5+ MY$]P<]FC)IYBLQT#Z"3E>3]OZT"Z-7+*63X^(BN,U=2.Y+"A&OI]Y*\TXDOM M=I*K%95GM]#8@?3J])3S>\2 K50SF]BQ%:8K#XPNA/K,8TW/C$7=0/:9FFO M%5PL\%IH!XS1K,Y0[',*I!S(2*V4_.,>@MIJJREN)9S=FX!69/EN4 !UP!YU MNHSWAQ0,$@T*WD8EV<_ENI1CM2.8JC%;7P.U6D.,4DL%I(+K@#T:I)E*QQY. MA,PM+9AD0@+*-I0E^\8S(9TZIENY@CV,:6A^L&Q@V;3.DP(HNJB6TAE#/46E MP5L%*B1 M(64^)).0;->HKV/8W7*IO9_4@>W8H5EN;@LSL@/V:!17MHDDP#D#4@HDG#8- M,^%\B]BS;*.AM&(>HW2#A2KX[AG))+'13BFQ/5>E:Z3W.$(-B]ESB,WU:U5: M<ZA6OPU[Q7N 5KSVOC.7A'9O3'6F*\1S9 M@D^J0K4N.<&ZYI&*L@:'*#SIC7!6W"*0;+6 M+B5LUSRCE]=@G'035CHGI[7GGGO*A1_]C3>U6_QZ< O.TD&DG'WY&>M74@\QHYE5^1)IF6&/NY5:^) M1/=K2LS/K56(G1R;I.5Y+K=W(-<&2>5\)S!(<&T\M\Y0L&72<@-O,<>:F] SDW2*KLDV^>EMN=H@75!=%J=U.MK6B M\E07&CN09YV>&ULS9I;C^(V%,??*_4[N/2AK=00 M"+WLH)E=,0R[0IT+ MJN^K(RSB%8F]C(-@-\^QZ'RW))@O>AN#QP2?ZVS_]W M'">'Y/;=*DO)*RC-I;BK->N-&@'!9,Q%<'1AYF5&5TKB"CPIHBG5=3W_?5E?.UXLG,D!_9 M3\0.0_K!:"]":C&2ZL*'HGTE?L#KII"D9VA::#$&#>H5XVUW*Q>>V M?9N@/X*@A6ZO-+^KS8R9M\-PN5S6EZVZ5 GZ:33#CT^/(S;#N (N+' &M5TK MVTM1N^;-S4V8[]U)SY2KB4IW8[3"73@HU[RM\^$>)=4F56=R2RT>\.NQ(F)@>;M M9@JF=[5,S%5@L])H12W;]?='(K.>XP35/)NGZ# \&!;SK7&*YCX?<<-1 U@9 M$#'$NV[LZ,Z!&6ZLNK%Y-4GPY7@(2*XD YH 3I:IQ(EG ]CPV(662G8436K3 M(4^,VV T1I-#U\#JB7P-8^#V2(CL%TLERHG@CT_YN)V)-HHRL^LII1-(\_X_ MH>9$$O[G,?4$HEH/(>%V3&&>:0;%H14KCR,\3&A',2)5# K3L.L1UX*C-)[/ MV*TBQ.1B1P$N'>E^!DR5S,I(;;G("^$>XL.AKD>XBVYP_>OCC%[] >LJQ&=2 M)\9-;XQ+K%T5\N[H'F./Q6R/%4Y((P](BXQ/Z4&C-Q]Q>C?'LJKE%LXFI$9(";IR@6??=5?&E9=M%QHZY>!W;SEPLNTA'6.ZZL=HD$_YIEA[7F23 M+T5(42)*FSBEX(VW%%RP>E7X?RMNL#;$,TRV$-MP=#'T$JD3[!L/L"NM717R M2*:*C*BQW=56X P4VQ2 8Y!?[]H\.]3*=EJT= M57HWV#[*P\LN?4+O:[T ];7H"UJY)GJV,.I\SU/X?+9\E#EAME'G5GF MR /63APC&+W]>.0"FE5\"^5NH/W5F14>_Q?$HZ\C'KD2]U%N7O3HCW@7O[ZH ML5P*!]Z'8C?:_BK.4G_^6.W4'_J!U(:F M__#YI1*_6.^&W5]=6>7RJM#MX=910,LQ'RO

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